| | Business Summary | | CuraGen
Corporation
is
a
genomics-based
biopharmaceutical
company.
The
Company
researches,
develops
and
uses
technologies
based
on
the
discovery
of
genes,
as
well
as
the
Company's
understanding
of
their
functions
and
relationships,
to
accelerate
the
discovery
and
development
of
products
to
improve
human
and
animal
health
and
the
vitality
of
agriculture,
in
collaboration
with
other
companies
and
through
the
Company's
proprietary
internal
programs.
The
Company's
genomics
technologies
and
information
systems
are
comprised
of
four
primary
components:
SeqCalling,
GeneCalling,
PathCalling
and
SNPCalling.
The
Company
may
also
provide
certain
support
services
necessary
to
characterize
gene
and
target
discoveries,
subscriptions
to
its
databases
and
integration
with
a
collaborator's
existing
development
pipeline
of
products.
The
Company
uses
its
GeneScape
software
platform
in
such
collaborations
to
manage
its
processes
and
provide
access
to
the
Company's
databases. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | CRGN
is
a
genomics
based
biopharmaceutical
company
that
is
advancing
the
discovery
and
development
of
pharmaceutical
and
life
science
products
through
the
systematic
application
of
genomics.
For
the
six
months
ended
6/30/01,
revenues
rose
12%
to
$11.9
million.
Net
loss
rose
38%
to
$15.6
million.
Results
reflect
increased
amounts
earned
under
collaborative
R&D
agreements,
offset
by
increased
research
and
development
and
personnel
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jonathan Rothberg, Ph.D., 37
Chairman,
Pres, CEO | $429K | -- | David Wurzer, 42
Exec.
VP, Treasurer and CFO | 320K | $3.3M | Christopher McLeod, 45
Exec.
VP | 315K | -- | Hovan Asdourian, 51
Sr.
VP, Bus. Devel. | 163K | -- | Michael McKenna, Ph.D., 38
VP-
Operations | 201K | 2.2M | | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/c/crgn.gif)